CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.
Immunotherapy
; 9(11): 929-941, 2017 09.
Article
en En
| MEDLINE
| ID: mdl-29338610
ABSTRACT
Following cancer treatment, patients often report behavioral and cognitive changes. Novel cancer immunotherapeutics have the potential to produce sustained cancer survivorship, meaning patients will live longer with the side effects of treatment. Given the role of inflammatory pathways in mediating behavioral and cognitive impairments seen in cancer, we aim in this review to discuss emerging evidence for the contribution of immune checkpoint blockade to exacerbate these CNS effects. We discuss ongoing studies regarding the ability of immune checkpoint inhibitors to reach the brain and how treatment responses to checkpoint inhibitors may be modulated by genetic factors. We further consider the use of preclinical tumor-models to study the role of tumor status in CNS effects of immune checkpoint inhibitors and multimodality therapy.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Sistema Nervioso Central
/
Síndromes de Neurotoxicidad
/
Evaluación Preclínica de Medicamentos
/
Terapia Molecular Dirigida
/
Antineoplásicos Inmunológicos
/
Neoplasias
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Immunotherapy
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Año:
2017
Tipo del documento:
Article